Loading...
Docoh

Azenta (AZTA)

Filed: 17 Nov 21, 7:00pm

Exhibit 99.1

Investor_investor_page_01.gif

FinancialOverview–Driving Growth Lindon Robertson, EVP and Chief Financial Officer


Investor_investor_page_02.gif

A G E N D A Financial Overview – Driving Growth Strong performance track record Disciplined capital allocation Outlook: Compelling growth ahead 2 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_03.gif

The Growth Continues — Building a Powerhouse in Life Sciences FY2019 FY2021 4% 17% Non-GAAP financial measures – see reconciliation tables. Based on continuing operations © 2021 Brooks Automation, Inc. • Proprietary Information 3 Employees~2,300~2,900 Customers>7,000>8,700 Adjusted EBITDA*$14M$86M Gross Margin*42%50% Revenue$334M$514M


Investor_investor_page_04.gif

Significant Shareholder Value Creation Brooks Enterprise Value ($M) $94,000 B $8,000 $7,000 $3,000 $6,000 $5,000 $2,000 $4,000 services $3,000 Entered Life Sciences crosses Ultra-cold services $1,000 $2,000 2010 $1,000 EV $275M over breakeven $0 22001100 20121011 201220122013 20123014 20210415 20165 20210716 20128017 2019 2018202020T1o9day 4 © 2021 Brooks Automation, Inc. • Proprietary Information Today EV >$8 2019 GenomicEV ~$2.6B Services Genomic Sample repositoryServices EnteredUltra-cold Life SciencesautomationSample repository Life Sciencesautomationover breakeven Average organic growth of 22% Life Sciences crosses2019-2021


Investor_investor_page_05.gif

Strong Track Record of Growth Revenue ($M) Gross Margin* ($M) EPS* ($M) 24% CAGR +8 bps +$0.79 $0.48 $514 50% $389 46% $334 $0.02 42% $(0.31) FY'19 FY'20 FY'21 FY'19 FY'20 FY'21 FY'19 FY'20 FY'21 Non-GAAP financial measures – see reconciliation tables. Based on continuing operations © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_06.gif

Azenta Now Generating Meaningful Cash Flow Cash flow positive Note: OCF represents Management’s view on a stand-alone basis © 2021 Brooks Automation, Inc. • Proprietary Information 6 Operating Cash Flow (OCF) $100M Ability to invest for the future •R&D •Sales organization •Capex •M&A $0 FY'19FY'20FY'21


Investor_investor_page_07.gif

Track Record of Organic Growth Supplemented by M&A Revenue $600 $ millions Acquisitions $500 $400 $300 Organic $200 $100 $-FY15 FY16 FY17 FY18 FY19 FY20 FY21 7 © 2021 Brooks Automation, Inc. • Proprietary Information 40% CAGR


Investor_investor_page_08.gif

Diverse Revenue Profile Aligned for Higher Growth 17% Sample & Repository Solutions 17% Gene Synthesis & Other 25% Consumables & Instruments 11% Sanger Sequencing 14% Ultra-Cold Automated Stores (and Service) 16% Next Gen Sequencing Contributes recurring revenue Note: Azenta revenue composition as of FY21 © 2021 Brooks Automation, Inc. • Proprietary Information 8


Investor_investor_page_09.gif

A G E N D A Financial Overview – Driving Growth Strong performance track record Disciplined capital allocation Outlook: Compelling growth ahead 9 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_10.gif

Strong Balance Sheet With Cash Generation and Proceeds from Semi Divestiture for Investment Operational CapEx Research and Development Investment Prioritizing cash for M&A opportunities and organic investment Note: Suzhou, China building project adds 3-4 points to CAPEX % of revenue in 2020 -22 © 2021 Brooks Automation, Inc. • Proprietary Information 10 ~4-6% of Revenue ~6-8% of Revenue >$2.5B Net Cash for M&A


Investor_investor_page_11.gif

Proven Track Record in Successful M&A: Capital 10 Years, >10 Transactions, ~$1B with ROIC Focus 11 © 2021 Brooks Automation, Inc. • Proprietary Information Acquisition Focus •Strategic fit to add value •ROIC > WACC in 5-7 years −High growth −Profit leverage


Investor_investor_page_12.gif

From Brooks to Standalone Azenta: ROIC Transformation Life Science company Portfolio continuously repositioned for faster growth and improvement © 2021 Brooks Automation, Inc. • Proprietary Information of ROIC 12 Transformative Portfolio Actions  2016 Restructuring for profitability and BioStorage acquisition  2019 GENEWIZ acquisition & Cryo divestiture set the stage for higher growth  2022 Semi divestiture will establish standalone >$2.5B of cash available for further steps of transformation ROIC Trend 2016201720182019202020212022E2024 Target Total BrooksAzenta Standalone 14% ~12% 13% 10% 7% 7% 2%


Investor_investor_page_13.gif

A G E N D A Financial Overview – Driving Growth Strong performance track record Disciplined capital allocation Outlook: Compelling growth ahead 13 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_14.gif

Strategy Going Forward 1 2 3 4 Extend leadership in core markets Invest for organic growth and strategic M&A Drive margin expansion Utilize balanced and disciplined capital deployment with ROIC focus 14 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_15.gif

Achieved FY2022 Goal 1-Year Ahead of Schedule Clear Goals Operating Performance ($M) Revenue $M $800 Gross Margin 55% • FY2022 goal set in September 2019 at our last Investor Day $700 50% Gross Margin Target Range $600 • We achieved the FY2022 goal inside of FY2021 45% $500 Revenue Target 40% • Strong execution on top and bottom line $400 35% $300 30% $200 25% $100 $-20% FY’19 FY’20 FY’21 Prior FY’22 Goal *Non-GAAP financial measures – see reconciliation tables. © 2021 Brooks Automation, Inc. • Proprietary Information 15 Revenue Gross Margin


Investor_investor_page_16.gif

Azenta 3-Year Target Model Operating Business Segments, FY 2024 Goal ~12% 16 © 2021 Brooks Automation, Inc. • Proprietary Information ROIC of EBITDA Margin ~26% Revenue CAGR FY’21-24 ~18% Life Science Services • Revenue range$520-570M • Gross Margin target52-54% • Operating expense productivity % of Azenta revenue ~65% EBITDA Margin 28-30% Life Science Products • Revenue growth to$280-310M • Gross Margin target47-49% • Operating expense productivity % of Azenta revenue ~35% EBITDA Margin 20-24%


Investor_investor_page_17.gif

2 0 2 4 M O D E L : Operating Leverage — A Key Driver Going Forward panding EBITDA Margins… 25-27% Opex % Rev 0 FY'21 FY'22 FY'23 FY'24 Pro Forma Standalone Pro forma adjusted for standalone costs estimated by management *Non-GAAP financial measures – see reconciliation tables. © 2021 Brooks Automation, Inc. • Proprietary Information 17 +9pts 19% 17% Ex 10% 7% FY'2 Leveraging Infrastructure, Expanding Gross Margins… 50%50–52% Gross Margin 46% 44%41% 38% 31-33% FY'20FY'21FY'22FY'23FY'24 Pro Forma Standalone $M Growing Revenue… $800-$880 CAGR FY'20FY'21FY'22FY'23FY'24 18% $514 $389


Investor_investor_page_18.gif

Azenta – Strong Growth and Margin Expansion to 2024 Revenue ($M) Adjusted EBITDA* ($M) Earnings Per Share* ~37% CAGR $200-240 ~18% CAGR ~3.5X $1.50-1.90 $800-880 $514 $86 $0.48 FY'21 FY'24E FY'21 FY'24 FY'21 FY'24E Non-GAAP financial measures – see reconciliation tables. © 2021 Brooks Automation, Inc. • Proprietary Information 18


Investor_investor_page_19.gif

W H Y All N O W : the Building Blocks In Place to Unlock Our Full Potential Capital Deployment Size and Scale Profitability Cash Flow We have solidified the foundation for a strong, standalone, life sciences company 19 © 2021 Brooks Automation, Inc. • Proprietary Information Strong cash flow to support capital investment and drive FCF 14 successful, accretive acquisitions Solidly positive operating margin and EPS Broad differentiated portfolio with >$500M run-rate revenue


Investor_investor_page_20.gif

K E Y T H E M E S Y O U H E A R D T O D A Y Building on Core Strengths. Forging New Growth Paths. $500M+ revenue company with growth opportunities through 2024 and beyond By 2024 Revenue $800-880M Adj. EBITDA* $200-240M EPS* $1.50-1.90 1 High-teens AND profitable growth with cash generation 2 Strong balance sheet with an experienced and capable team 3 Capital to deploy >$2.5B Global platform that can support more capabilities and customers 4 20 © 2021 Brooks Automation, Inc. • Proprietary Information *Non-GAAP financial measures


Investor_investor_page_21.gif

1st As of December we will change our parent company name and ticker to: Azenta, Inc. (NASDAQ: AZTA) A Unique Life Sciences Company © 2021 Brooks Automation, Inc. • Proprietary Information 21


Investor_investor_page_22.gif

Q&A © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_23.gif

Appendix


Investor_investor_page_24.gif

Azenta 3-Year FY2024 Goal Target Model – Continuing Operations * Non-GAAP financial measures © 2021 Brooks Automation, Inc. • Proprietary Information 24 FY 2024 Goal $800-880M $520-570M $280-310M 50-52% ~32% $150-190M 19-22% $200-240M $1.50-1.90 $M except EPSFY 2019FY 2020FY 2021 Total Revenue $334M $389M Life Science Services $215M $259M Life Science Products $119M $130M $514 $314 $200 Gross Margin*42%46% 50% Operating Expenses* % of Revenue46%46% 41% Operating Income*($12M)$0M % of Revenue(4%)0% $47M 9% EBITDA*$14M$28M EPS*($0.31)$0.02 $86M $0.48


Investor_investor_page_25.gif

Azenta 3-Year FY2024 Goal Target Model – Standalone Basis The standalone P&L’s reflect pro-forma adjustments to exclude certain corporate costs reported in Continuing operations that management anticipates will no longer be incurred upon completion of the divestiture. * Non-GAAP financial measures © 2021 Brooks Automation, Inc. • Proprietary Information 25 FY 2024 Goal $800-880M $520-570M $280-310M 50-52% ~32% $150-190M 19-22% $200-240M $1.50-1.90 $M except EPSFY 2019FY 2020FY 2021 Total Revenue $334M $389M Life Science Services $215M $259M Life Science Products $119M $130M $514 $314 $200 Gross Margin*42%46% 50% Operating Expenses* % of Revenue45%44% 38% Operating Income*($9M)$8M % of Revenue(3%)2% $61M 12% EBITDA*$17M$37M EPS*($0.10)$0.07 $96M $0.63


Investor_investor_page_26.gif

GAAP to Non-GAAP Reconciliation Continuing Operations $ millions, except EPS FY 2019 FY 2020 FY 2021 FY 2019 FY 2020 FY 2021 Revenue GAAP gross profit Gross profit margin Amortization expense Tariffs Restructuring related charges Other special charges Non-GAAP gross profit Non-GAAP gross profit margin GAAP operating expenses Merger and acquisition costs Amortization expense Restructuring charges Other special charges Non-GAAP operating expenses GAAP operating loss Operating profit margin Non-GAAP operating profit (loss) Non-GAAP operating profit margin GAAP net loss Merger and acquisition costs Amortization expense Restructuring and related charges Other special charges Tariffs Loss on extinguishment of debt Tax related adjustments Tax effect of adjustments Non-GAAP net income (loss) Diluted earnings per share Non-GAAP diluted earnings per share 334 135 40% 7 - 0 - 142 42% (182) 7 20 1 - (154) (47) -14% (12) -4% (61) 7 27 2 - - 14 1 (13) (23) (0.84) (0.31) 389 172 44% 8 - 0 - 181 46% (209) 1 27 1 - (180) (37) -9% 0 0% (26) 1 35 1 - - - (1) (8) 1 (0.36) 0.02 514 244 47% 8 5 - (0) 257 50% (275) 21 29 0 14 (210) (31) -6% 47 9% (29) 21 37 0 14 5 - (12) (1) 36 (0.39) 0.48 Life Science s Products Revenue GAAP gross profit Gross profit margin Amortization expense Non-GAAP gross profit Non-GAAP gross profit margin Operating expenses GAAP operating profit (loss) Operating profit margin Non-GAAP operating profit (loss) Non-GAAP operating profit margin $ 119 44 37% 1 45 38% (66) (22) -19% (21) -18% $ 130 56 43% 1 57 44% (60) (4) -3% (3) -2% $ 200 93 46% 1 94 47% (71) 22 11% 23 12% FY 2019 FY 2020 FY 2021 Life Sciences Services Revenue GAAP gross profit Gross profit margin Amortization expense Tariff and other special charges Non-GAAP gross profit Non-GAAP gross profit margin Operating expenses GAAP operating profit (loss) Operating profit margin Non-GAAP operating profit Non-GAAP operating profit margin $ 215 91 42% 6 0 97 45% (88) 3 1% 9 4% $ 259 116 45% 7 0 124 48% (121) (4) -2% 3 1% $ 314 151 48% 7 5 164 52% (141) 10 3% 23 7% 26 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_27.gif

Net Income Reconciliation Continuing Operations $ millions to Adjusted EBITDA FY'19 FY20 FY'21 Life Science Products FY19 FY20 FY21 Operating Profit (Loss) Adjustments: Depreciation Amortization of intangible assets EBITDA EBITDA margin Adjustments: Stock-based compensation Adjusted EBITDA Adjusted EBITDA margin (22.1) (4.2) 22.0 Net income Income from discontinued operations, net of tax Net income from continuing operations 437.4 (498. 5) 64.9 (91. 2) 110.7 (139.6) 3.0 1.2 3.3 1. 2 3.5 1. 1 (61.1) (26.4) (28.9) (17.9) -15.1% 0.3 0.2% 26.6 13.3% Adjustments: Interest income Interest expense Income tax provision Depreciation Amortization of intangible assets EBITDA-from Continuing Operations (1.4) 22.2 (22.8) 14.0 27.3 (0.8) 2.9 (13.9) 18.7 35.4 (0.6) 2.0 (20.1) 19.5 37.4 7. 1 3. 7 6. 6 (10.8) -9.1% 4.0 3.1% 33.2 16.6% (7.5) 15.9 9.3 Life Science Services FY19 FY20 FY21 Operating Profit (Loss) Adjustments: Depreciation Amortization, restructuring related, and other special charges 3.1 (4.4) 10.3 Adjustments: Stock-based compensation Rebranding and transformation Tax indemnification reserve release Impairment of trademark Tariff adjustment Restructuring charges Merger and acquisition costs / Other Adjusted EBITDA - from Continuing Operations Adjusted EBITDA margin 13.1 - - - - 1.7 6.7 10.8 - - - - 1.0 0.5 20.1 0.8 16.0 13.4 5.4 0.4 20.7 14.0 15.0 15.1 5.9 7.2 6.9 EBITDA EBITDA margin Adjustments: Tariff adjustment Stock-based compensation Adjusted EBITDA Adjusted EBITDA margin 22.9 10.7% 17.9 6.9% 32.3 10.3% - 6.0 - 7. 1 5.5 13. 5 13.9 4.2% 28.2 7.3% 86.0 16.7% 28.9 13.4% 25.0 9.6% 51.2 16.3% 27 © 2021 Brooks Automation, Inc. • Proprietary Information


Investor_investor_page_28.gif

GAAP to Non-GAAP Reconciliation Total Brooks – Continuing Operations $ millions, except EPS - Standalone FY 2019 FY 2020 FY 2021 Revenue GAAP gross profit Gross profit margin Non-GAAP Adjustments Non-GAAP gross profit Non-GAAP gross profit margin Non-GAAP standalone gross profit Non-GAAP standalone gross profit margin 334 135 40% 7 142 42% 142 42% 389 172 44% 8 181 46% 181 46% 514 244 47% 14 257 50% 257 50% GAAP operating expenses Non-GAAP adjusments Non-GAAP operating expenses Standalone adjustments Non-GAAP standalone operating expenses (182) 29 (154) 3 (150) (209) 28 (180) 8 (173) (275) 65 (210) 15 (196) GAAP operating loss Operating profit margin Non-GAAP operating profit (loss) Non-GAAP operating profit margin Standalone adjustments Non-GAAP standalone operating profit (loss) Non-GAAP standlone operating profit margin (47) -14% (12) -4% 3 (9) -3% (37) -9% 0 0% 8 8 2% (31) -6% 47 9% 14 62 12% GAAP net loss Merger and acquisition costs Amortization expense Restructuring and related charges Other special charges Tariffs Loss on extinguishment of debt Tax related adjustments Tax effect of adjustments Non-GAAP net income (loss) Non-GAAP standlone net income (loss) Diluted earnings per share Non-GAAP diluted earnings per share Standalone Non-GAAP diluted earnings per shar (61) 7 27 2 - - 14 1 (13) (23) (7) (0.84) (0.31) (0.10) (26) 1 35 1 - - - (1) (8) 1 5 (0.36) 0.02 0.07 (29) 21 37 0 14 5 - (12) (1) 36 47 (0.39) 0.48 0.63 The standalone P&L’s reflect pro-forma adjustments to exclude certain corporate costs reported in Continuing operations 28 that management anticipates will no longer be incurred upon completion of the divestiture. © 2021 Brooks Automation, Inc. • Proprietary Information